Caredx, Inc. income statement
In fiscal 2025, Caredx, Inc. reported revenue of $380m, up 13.8% on the year before, operating income of −$30.8m (a -8.1% margin) and net income of −$21.4m, or −$0.40 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20 | 22 | 27 | 28 | 41 | 48 | 77 | 127 | 192 | 296 | 322 | 280 | 334 | 380 | 497 |
| Cost of revenue | — | — | — | — | — | 21 | 33 | 45 | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | 27 | 44 | 82 | — | — | — | — | — | — | — |
| Research and development | 5 | 3 | 4 | 9 | 12 | 12 | 15 | 31 | 49 | 77 | 90 | 82 | 73 | 71 | 84 |
| Selling and marketing | 5 | 6 | 6 | 8 | 11 | 13 | 22 | 39 | 54 | 77 | 96 | 84 | 82 | 103 | 126 |
| General and administrative | 5 | 5 | 8 | 12 | 21 | 20 | 23 | 37 | 49 | 75 | 100 | 119 | 125 | 108 | 138 |
| Operating income | −2 | −1 | 1 | −12 | −37 | −20 | −16 | −25 | −23 | −30 | −77 | −203 | 41 | −31 | 116 |
| Interest expense | 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net interest income | −3 | −2 | −2 | −2 | −2 | — | — | — | — | — | — | — | — | — | — |
| Income before tax | −5 | −4 | −1 | −14 | −41 | −57 | −48 | −24 | −20 | −32 | −76 | −190 | 53 | −21 | 124 |
| Income tax | 0 | 0 | −2 | 0 | −2 | −2 | −1 | −2 | −1 | −1 | 0 | 0 | 0 | 0 | −4 |
| Net income | −5 | −4 | 1 | −14 | −39 | −55 | −47 | −22 | −19 | −31 | −77 | −190 | 53 | −21 | 129 |
| Diluted EPS | −$5.01 | −$3.50 | $0.10 | −$1.16 | −$2.39 | −$2.38 | −$1.31 | −$0.52 | −$0.40 | −$0.59 | −$1.44 | −$3.54 | $0.93 | −$0.40 | $2.43 |
| Diluted shares (average) | 1m | 1m | 9m | 12m | 16m | 23m | 36m | 42m | 46m | 52m | 53m | 54m | 57m | 53m | 53m |
| EBITDA | −1 | −0 | 2 | −11 | −34 | −17 | −11 | −19 | −16 | −21 | −66 | −189 | 55 | −16 | 134 |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 87 | 85 | 87 | 100 | 108 | 118 | 132 | 139 |
| Research and development | 17 | 19 | 17 | 17 | 19 | 21 | 22 | 21 |
| Selling and marketing | 21 | 23 | 24 | 24 | 31 | 30 | 33 | 32 |
| General and administrative | 32 | 23 | 28 | 28 | 29 | 30 | 41 | 38 |
| Operating income | 84 | −13 | −11 | −0 | −6 | 1 | 113 | 8 |
| Income before tax | 88 | −10 | −9 | 2 | −4 | 3 | 115 | 11 |
| Income tax | 0 | 0 | −0 | −0 | 0 | −0 | 4 | −9 |
| Net income | 88 | −10 | −9 | 2 | −4 | 3 | 111 | 19 |
| Diluted EPS | $1.60 | −$0.19 | −$0.16 | $0.03 | −$0.08 | $0.05 | $2.07 | $0.35 |
| EBITDA | 88 | −10 | −7 | 4 | −2 | 5 | 116 | 15 |
Compare with peers
- Starling Oncology, Inc. income statement
- U S Physical Therapy Inc income statement
- Viemed Healthcare, Inc. income statement
- Docgo Inc. income statement
- DLH Holdings Corp. income statement
Head to head: CDNA vs STLNCDNA vs USPHCDNA vs VMD
More: Health Care Services stocks compared, Health Care sector, rankings of US companies